Cargando…

Clinicopathologic Features of Acute Kidney Injury Associated With CDK4/6 Inhibitors

Detalles Bibliográficos
Autores principales:	Gupta, Shruti, Caza, Tiffany, Herrmann, Sandra M., Sakhiya, Vipulbhai C., Jhaveri, Kenar D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897293/ https://www.ncbi.nlm.nih.gov/pubmed/35257075 http://dx.doi.org/10.1016/j.ekir.2021.11.033

Ejemplares similares

SAT-128 Evaluating the Accuracy of Glycemic Markers and Risk of Hypoglycemia in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease by Continuous Glucose Monitoring
por: Presswala, Lubaina, et al.
Publicado: (2019)

Adverse Renal Effects of Novel Molecular Oncologic Targeted Therapies: A Narrative Review
por: Jhaveri, Kenar D., et al.
Publicado: (2016)

Outcomes of patients with end-stage kidney disease hospitalized with COVID-19
por: Ng, Jia H., et al.
Publicado: (2020)

Outcomes Among Patients Hospitalized With COVID-19 and Acute Kidney Injury
por: Ng, Jia H., et al.
Publicado: (2021)

Glomerular diseases post-hematopoietic stem cell transplantation: pathologic spectrum and plausible mechanisms
por: Caza, Tiffany N, et al.
Publicado: (2023)

Anaplastic lymphoma kinase inhibitors and their effect on the kidney
por: Bonilla, Marco, et al.
Publicado: (2022)

The Relationship Between Medication Discrepancies and Hospitalization Risk Among Patients With Advanced CKD
por: Sakhiya, Vipul, et al.
Publicado: (2019)

COVID-19 therapeutic options for patients with kidney disease
por: Izzedine, Hassan, et al.
Publicado: (2020)

Clinicopathological Features Related to the Efficacy of CDK4/6 Inhibitor-Based Treatments in Metastatic Breast Cancer
por: Shikanai, Ayana, et al.
Publicado: (2022)

Revisiting the role of acute kidney injury in patients on immune checkpoint inhibitors: a good prognosis renal event with a significant impact on survival
por: García-Carro, Clara, et al.
Publicado: (2023)

Adverse kidney outcomes of CDK 4/6 inhibitors for metastatic breast cancer
por: Hanna, Paul E., et al.
Publicado: (2023)

Pregnancy outcomes in women on hemodialysis: a national survey
por: Sachdeva, Mala, et al.
Publicado: (2017)

Acute Kidney Injury in the Patient with Cancer
por: Meraz-Munoz, Alejandro, et al.
Publicado: (2021)

Pathology of COVID-19-associated acute kidney injury
por: Sharma, Purva, et al.
Publicado: (2021)

Renal effects of BRAF inhibitors: a systematic review by the Cancer and the Kidney International Network
por: Wanchoo, Rimda, et al.
Publicado: (2016)

Cardio–renal service, time for a change
por: Uppal, Nupur N, et al.
Publicado: (2021)

Clinicopathological Features of Kidney Injury Related to Immune Checkpoint Inhibitors: A Systematic Review
por: Xu, Ling-Yi, et al.
Publicado: (2023)

Continuous Glucose Monitoring and Glycemic Control in Patients With Type 2 Diabetes Mellitus and CKD
por: Presswala, Lubaina, et al.
Publicado: (2019)

Does treating with anti–PD-1 to improve glomerular health come without a cost?
por: Jhaveri, Kenar D., et al.
Publicado: (2022)

Nirogacestat and Hypophosphatemia
por: Gudsoorkar, Prakash, et al.
Publicado: (2023)

Immune checkpoint inhibitor use in patients with end-stage kidney disease: an analysis of reported cases and literature review
por: Kitchlu, Abhijat, et al.
Publicado: (2021)

Genes, COVID-19 and phenotype
por: Izzedine, Hassan, et al.
Publicado: (2021)

Pathophysiology and Pathology of Acute Kidney Injury in Patients With COVID-19
por: Ng, Jia H., et al.
Publicado: (2020)

Selective CDK inhibitors: promising candidates for future clinical traumatic brain injury trials
por: Kabadi, Shruti V., et al.
Publicado: (2014)

Immune checkpoint inhibitor related nephrotoxicity: Advances in clinicopathologic features, noninvasive approaches, and therapeutic strategy and rechallenge
por: Miao, Jing, et al.
Publicado: (2022)

The authors reply
por: Wanchoo, Rimda, et al.
Publicado: (2020)

Clinicopathological and Dermoscopic Features in Blashkoid Angioma Serpiginosum
por: Dhanta, Aditi, et al.
Publicado: (2021)

Inducible deletion of CDK4 and CDK6 – deciphering CDK4/6 inhibitor effects in the hematopoietic system
por: Maurer, Barbara, et al.
Publicado: (2020)

Management of hypertension in patients with cancer: challenges and considerations
por: Pandey, Shubhi, et al.
Publicado: (2023)

The Therapeutic Potential of CDK4/6 Inhibitors, Novel Cancer Drugs, in Kidney Diseases
por: Liang, Xuan-Bing, et al.
Publicado: (2023)

Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER‐positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor
por: Karimi, Leena, et al.
Publicado: (2023)

Acute kidney injury in patients hospitalized with COVID-19
por: Hirsch, Jamie S., et al.
Publicado: (2020)

Comparison of clinicopathological features between patients with and without hypocomplementemia in IgG4-related kidney disease
por: Saeki, Takako, et al.
Publicado: (2022)

Risk factors associated with post–kidney transplant malignancies: an article from the Cancer-Kidney International Network
por: Sprangers, Ben, et al.
Publicado: (2018)

A letter to the Master Clinician
por: Jhaveri, Kenar D.
Publicado: (2014)

CDK 4/6 inhibitors for the treatment of meningioma
por: Young, Jacob S., et al.
Publicado: (2022)

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
por: Al-Qasem, Abeer J., et al.
Publicado: (2022)

Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders
por: Wu, Xuewei, et al.
Publicado: (2021)

CDK6 Immunophenotype Implicates Potential Therapeutic Application of CDK4/6 Inhibitors in Urothelial Carcinoma
por: Sun, Ran, et al.
Publicado: (2022)

Allostery governs Cdk2 activation and differential recognition of CDK inhibitors
por: Majumdar, Abir, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_s3csgu724svkpgb2d5jpqmou7v